Exploring the biological behavior and underlying mechanism of KITLG in triple-negative breast cancer

Liuqing Qin1, Yuchao Li1, Yifei Huang1

  • 1Department of Gastrointestinal Gland Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China.

Journal of Cancer
|January 12, 2024
PubMed

Insights

KITLG, a factor crucial for cell development, shows low expression in triple-negative breast cancer (TNBC), correlating with poor survival. This suggests KITLG may suppress tumors, offering a potential new prognostic marker for TNBC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • KITLG (KIT ligand) is a factor involved in cell development, migration, and hematopoiesis.
  • KITLG mutations are linked to germ cell tumors, but its role in breast cancer is unclear.
  • Triple-negative breast cancer (TNBC) has limited targeted therapy options.

Purpose of the Study:

  • To investigate the role and expression patterns of KITLG in breast cancer, particularly TNBC.
  • To explore KITLG as a potential prognostic marker and therapeutic target for TNBC.

Main Methods:

  • Analysis of gene expression data from multiple independent databases, including the GEO database.
  • Correlation analysis between KITLG expression levels and patient survival rates in TNBC and non-TNBC tissues.

Main Results:

  • Consistently low KITLG expression was observed in TNBC tissues, associated with reduced survival rates.
  • Non-TNBC tissues exhibited significantly higher KITLG expression compared to normal tissues.
  • Preliminary analysis suggests KITLG may function as an oncogene suppressor in TNBC.

Conclusions:

  • KITLG expression patterns differ significantly between TNBC and non-TNBC.
  • KITLG shows promise as a novel prognostic marker for TNBC.
  • Further research into KITLG's mechanisms could inform new therapeutic strategies for TNBC.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K